Welcome to our dedicated page for ACLARION news (Ticker: ACONW), a resource for investors and traders seeking the latest updates and insights on ACLARION stock.
Aclarion, Inc. develops healthcare technology for chronic low back pain care, with news centered on Nociscan, its software-as-a-service platform that uses magnetic resonance spectroscopy data, proprietary signal processing, biomarkers and augmented intelligence algorithms to help physicians distinguish painful from nonpainful lumbar discs.
Company updates commonly address commercial adoption, clinical-site agreements, physician education, AI-enabled clinical decision support, shareholder communications, investor-conference participation and governance actions such as a stockholder rights plan. Aclarion also reports through Nasdaq-traded common stock and warrants under ACON and ACONW.
Aclarion, Inc. has successfully closed its initial public offering (IPO), raising approximately $9.4 million through the sale of 2,165,000 shares of common stock and accompanying warrants at a price of $4.35 per share. The IPO began trading on April 22, 2022, under the symbols ACON and ACONW. Maxim Group LLC served as the sole book-running manager and has exercised an option to purchase an additional 324,750 warrants. Aclarion focuses on using Magnetic Resonance Spectroscopy and AI to enhance treatments for the $134.5 billion U.S. low back and neck pain market.
Aclarion, Inc. (NASDAQ:ACON, ACONW) announced the pricing of its initial public offering, offering 2,165,000 shares of common stock and accompanying warrants at $4.35 each, generating approximately $9.4 million in gross proceeds. The offering is set to close on April 26, 2022, pending customary conditions. Additionally, Aclarion has granted underwriters a 45-day option to purchase up to 324,750 additional shares. This IPO aims to enhance the company's healthcare technology, leveraging Magnetic Resonance Spectroscopy and artificial intelligence for pain management.